Manufacturer of Controlled Substances; Notice of Application, 33923 [05-11479]

Download as PDF Federal Register / Vol. 70, No. 111 / Friday, June 10, 2005 / Notices (‘‘IA’’) on January 21, 2005. All parties filed responses to the petitions on January 28, 2005. On February 24, 2005, the Commission issued a notice indicating that it has determined not to review the ALJ’s final ID on violation, thereby finding a violation of section 337. The Commission also called for briefing on the issues of remedy, the pubic interest and bonding. All parties filed timely written submissions regarding those issues. On April 7, 2005, the Commission issued a limited exclusion order and a cease and desist order covering AMT systems for medium-duty and heavy-duty trucks, and components thereof. 70 FR 19094 (April 13, 2005). On April 21, 2005, the respondents filed a request for issuance of an advisory opinion. The IA and the complainant each filed a response on May 2, 2005, and May 4, 2005, respectively. On May 11, 2005, the complainant filed a complaint for enforcement proceedings of the Commission’s remedial orders. On May 24, 2005, complaint amended its enforcement complaint. The Commission, having examined the amended complaint for a formal enforcement proceeding filed by the complainant, and having found that the amended complaint complies with the requirements for institution of a formal enforcement proceeding, determined to institute formal enforcement proceedings to determine whether the two respondents listed below are in violation of the Commission’s limited exclusion order and/or cease and desist order issued in the investigation, and what if any enforcement measures are appropriate. The following were named as parties to the formal enforcement proceeding: (1) Complainant Eaton Corporation (2) respondent ZF Friedrichshafen AG, (3) respondent ArvinMeritor, Inc.; and (4) a Commission investigative attorney to be designated by the Director, Office of Unfair Import Investigations. The Commission, having examined the request for an advisory opinion filed by the respondents, and having found that the request complies with the requirements for institution of advisory opinion proceedings, determined to institute advisory opinion proceedings to determine whether the importation of the respondents’ redesigned FreedomLine transmission system would violate the limited exclusion order issued in the above-captioned investigation. The following were named as parties to the advisory opinion proceedings.: (1) Complainant Eaton Corporation (2) respondent ZF Friedrichshafen AG, (3) respondent VerDate jul<14>2003 17:22 Jun 09, 2005 Jkt 205001 ArvinMeritor, Inc.; and (4) a Commission investigative attorney to be designated by the Director, Office of Unfair Import Investigations. The authority for the Commission’s determination is contained in section 337 of the Tariff of 1930, as amended (19 U.S.C. 1337), and in sections 210.75 and 210.79 of the Commission’s Rules of Practice and Procedure (19 CFR 210.75 and 210.79). By order of the Commission. Issued: June 6, 2005. Marilyn R. Abbott, Secretary to the Commission. [FR Doc. 05–11482 Filed 6–9–05; 8:45 am] BILLING CODE 4210–29–M DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 8, 2005, Research Triangle Institute, Kenneth H. Davis Jr., Hermann Building East Institute Drive, P.O. Box 12194, Research Triangle Park, North Carolina 27709, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedules I and II: Drug Schedule Marihuana (7360) ......................... Cocaine (9041) ............................. I II The Institute will manufacture small quantities of cocaine derivates and marihuana derivatives for use by their customers primarily in analytical kits, reagents and preference standards. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 33923 Alexandria, Virginia 22301; and must be filed no later than August 9, 2005. Dated: June 2, 2005. William J. Walker, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–11479 Filed 6–9–05; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Parole Commission Record of Vote of Meeting Closure (Public Law 94–409) (5 U.S.C. Sec. 552b); Sunshine Act I, Edward F. Reilly, Jr., Chairman of the United States Parole Commission, was present at a meeting of said Commission, which started at approximately 12 noon on Thursday, June 2, 2005, at the U.S. Parole Commission, 5550 Friendship Boulevard, 4th Floor, Chevy Chase, Maryland 20815. The purpose of the meeting was to decide case deliberations or review of two original jurisdiction cases conducting pursuant to 28 CFR 2.17 and 28 CFR 2.27. Five Commissioners were present, constituting a quorum when the vote to close the meeting was submitted. Public announcement further describing the subject matter of the meeting and certifications of General Counsel that this meeting may be closed by vote of the Commissioners present were submitted to the Commissioners prior to the conduct of any other business. Upon motion duly made, seconded, and carried, the following Commissioners voted that the meeting be closed: Edward F. Reilly, Jr., Cranston J. Mitchell, Deborah A. Spagnoli, Isaac Fulwood, Jr., and Patricia Cushwa. In witness whereof, I make this official record of the vote taken to close this meeting and authorize this record to be made available to the public. Dated: June 6, 2005. Edward F. Reilly, Jr., Chairman, U.S. Parole Commission. [FR Doc. 05–11620 Filed 6–8–05; 11:01 am] BILLING CODE 4410–01–M E:\FR\FM\10JNN1.SGM 10JNN1

Agencies

[Federal Register Volume 70, Number 111 (Friday, June 10, 2005)]
[Notices]
[Page 33923]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-11479]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on April 8, 2005, Research 
Triangle Institute, Kenneth H. Davis Jr., Hermann Building East 
Institute Drive, P.O. Box 12194, Research Triangle Park, North Carolina 
27709, made application by renewal to the Drug Enforcement 
Administration (DEA) to be registered as a bulk manufacturer of the 
basic classes of controlled substances listed in Schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Marihuana (7360)...........................  I
Cocaine (9041).............................  II
------------------------------------------------------------------------

    The Institute will manufacture small quantities of cocaine 
derivates and marihuana derivatives for use by their customers 
primarily in analytical kits, reagents and preference standards.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such written comments or objections being sent via regular mail 
may be addressed, in quintuplicate, to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, Washington, DC 20537, Attention: DEA Federal Register 
Representative, Liaison and Policy Section (ODL); or any being sent via 
express mail should be sent to DEA Headquarters, Attention: DEA Federal 
Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, 
Virginia 22301; and must be filed no later than August 9, 2005.

    Dated: June 2, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 05-11479 Filed 6-9-05; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.